AI assistant
CRISPR Therapeutics AG — Director's Dealing 2022
Feb 22, 2022
30936_dirs_2022-02-22_8f0a15c4-4e2e-4f76-8460-890a0a1469a1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2022-02-18
Reporting Person: Kulkarni Samarth (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-18 | Stock Option (Right to Buy) | $58.29 | A | 115000 | Acquired | 2032-02-18 | Common Shares (115000) | Direct |
| 2022-02-18 | Restricted Stock Units | $ | A | 53000 | Acquired | Common Shares (53000) | Direct |
Footnotes
F1: This option was granted on February 18, 2022 with respect to 115,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.
F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.